Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.

Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, Mendez LP, Rivera L, Innis BL, Jain VK.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):242-51. doi: 10.1093/jpids/piu098. Epub 2014 Oct 20.

2.

Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.

Halasa NB, Gerber MA, Berry AA, Anderson EL, Winokur P, Keyserling H, Eckard AR, Hill H, Wolff MC, McNeal MM, Edwards KM, Bernstein DI.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):214-24. doi: 10.1093/jpids/piu061. Epub 2014 Jun 27.

3.

Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Feng L, Yang P, Zhang T, Yang J, Fu C, Qin Y, Zhang Y, Ma C, Liu Z, Wang Q, Zhao G, Yu H.

Hum Vaccin Immunother. 2015;11(8):2077-101. doi: 10.1080/21645515.2015.1027470.

4.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14. Epub 2014 Jun 4.

5.

An evaluation of the emerging vaccines against influenza in children.

Nair H, Lau E, Brooks W, Seong A, Theodoratou E, Zgaga L, Huda T, Jadhav SS, Rudan I, Campbell H.

BMC Public Health. 2013;13 Suppl 3:S14. doi: 10.1186/1471-2458-13-S3-S14. Epub 2013 Sep 17. Review.

6.

Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.

Cao RG, Suarez NM, Obermoser G, Lopez SM, Flano E, Mertz SE, Albrecht RA, García-Sastre A, Mejias A, Xu H, Qin H, Blankenship D, Palucka K, Pascual V, Ramilo O.

J Infect Dis. 2014 Jul 15;210(2):224-33. doi: 10.1093/infdis/jiu079. Epub 2014 Feb 4.

7.

Assessing parents' knowledge and attitudes towards seasonal influenza vaccination of children before and after a seasonal influenza vaccination effectiveness study in low-income urban and rural Kenya, 2010-2011.

Oria PA, Arunga G, Lebo E, Wong JM, Emukule G, Muthoka P, Otieno N, Mutonga D, Breiman RF, Katz MA.

BMC Public Health. 2013 Apr 25;13:391. doi: 10.1186/1471-2458-13-391.

8.

Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.

Salleras L, Navas E, Torner N, Prat AA, Garrido P, Soldevila N, Domínguez A.

Hum Vaccin Immunother. 2013 Mar;9(3):707-11. Epub 2013 Jan 7.

9.

Rituximab-treated patients have a poor response to influenza vaccination.

Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE.

J Clin Immunol. 2013 Feb;33(2):388-96. doi: 10.1007/s10875-012-9813-x. Epub 2012 Oct 14.

10.

Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Smith JH, Papania M, Knaus D, Brooks P, Haas DL, Mair R, Barry J, Tompkins SM, Tripp RA.

Vaccine. 2012 Apr 19;30(19):3026-33. doi: 10.1016/j.vaccine.2011.10.092. Epub 2011 Nov 7.

11.

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.

Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, Abate G, Sakala IG, Edwards KM, Creech CB, Gerber MA, Bernstein DI, Newman F, Graham I, Anderson EL, Belshe RB.

J Infect Dis. 2011 Sep 15;204(6):845-53. doi: 10.1093/infdis/jir436. Epub 2011 Aug 15.

12.

The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.

Ambrose CS, Levin MJ, Belshe RB.

Influenza Other Respir Viruses. 2011 Mar;5(2):67-75. doi: 10.1111/j.1750-2659.2010.00183.x. Epub 2010 Nov 19. Review.

13.

Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands.

Bodewes R, de Mutsert G, van der Klis FR, Ventresca M, Wilks S, Smith DJ, Koopmans M, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Clin Vaccine Immunol. 2011 Mar;18(3):469-76. doi: 10.1128/CVI.00396-10. Epub 2011 Jan 5.

14.

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, Jones T, Kemble G, Dubovsky F.

PLoS One. 2010 Oct 29;5(10):e13755. doi: 10.1371/journal.pone.0013755.

15.

Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children.

Usonis V, Anca I, André F, Chlibek R, Ivaskeviciene I, Mangarov A, Mészner Z, Prymula R, Simurka P, Tamm E, Tesović G, Central European Vaccination Advisory Group.

BMC Infect Dis. 2010 Jun 14;10:168. doi: 10.1186/1471-2334-10-168. Review.

16.

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ.

BMJ. 2010 May 27;340:c2649. doi: 10.1136/bmj.c2649.

17.

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons.

Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, Treanor JJ.

BMC Infect Dis. 2010 Mar 17;10:71. doi: 10.1186/1471-2334-10-71.

18.

Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.

Milne G, Kelso J, Kelly H.

J R Soc Interface. 2010 Apr 6;7(45):573-86. doi: 10.1098/rsif.2009.0312. Epub 2009 Sep 15.

19.

Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, van den Brand JM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2009;4(5):e5538. doi: 10.1371/journal.pone.0005538. Epub 2009 May 14.

20.

Estimation of influenza vaccine effectiveness from routine surveillance data.

Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I.

PLoS One. 2009;4(3):e5079. doi: 10.1371/journal.pone.0005079. Epub 2009 Mar 31.

Supplemental Content

Support Center